Ultragenyx Pharmaceutical (RARE) Treasury Shares (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Treasury Shares of $10.0 million for Q1 2026, up 32.17% year-over-year from $7.6 million in Q1 2025, and up 25.0% quarter-over-quarter from $8.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Treasury Shares (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Treasury Shares for 4 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 32.17% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (up 32.17% YoY), while the FY2025 annual figure was $8.0 million, up 100.0% from the prior year.
- Treasury Shares advanced to $10.0 million in Q1 2026 per RARE's latest filing, from $8.0 million in the prior quarter.
- Across five years, Treasury Shares topped out at $300000.0 in Q1 2026 and bottomed at $7812.0 in Q1 2023.
- Historically, Treasury Shares has averaged $103094.8 across 4 years, with a median of $68923.0 in 2024.
- Annual changes were most pronounced in 2024 — Treasury Shares soared 835.96% — and 2026, when it jumped 32.17%.
- Ultragenyx Pharmaceutical's Treasury Shares stood at $432000.0 in 2023, then soared by 825.93% to $4.0 million in 2024, then surged by 100.0% to $8.0 million in 2025, then climbed by 25.0% to $10.0 million in 2026.
- Business Quant data shows RARE's Treasury Shares at $10.0 million in Q1 2026, $8.0 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.00 Mn |
| Jun 30, 2026 | 10.00 Mn |
| Jun 30, 2026 | 300,000.00 |
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 10.00 Mn |
| Mar 31, 2026 | 10.00 Mn |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 8.00 Mn |
| Dec 31, 2025 | 8.00 Mn |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 173,034.00 |
| Sep 30, 2025 | 173,034.00 |
| Sep 30, 2025 | 7.99 Mn |
| Sep 30, 2025 | 7.99 Mn |
| Jun 30, 2025 | 173,034.00 |
| Jun 30, 2025 | 7.99 Mn |
| Jun 30, 2025 | 7.99 Mn |
| Jun 30, 2025 | 173,034.00 |